Chicago Atlantic BDC: A Record Quarter as the Cannabis Rescheduling Wave Approaches
The niche lender posts record NII and deployment, files a $500M shelf, and stands to benefit from a once-in-a-generation federal policy shift.
LIEN · Earnings Call · 2026-05-14
A Different Kind of BDC
Chicago Atlantic BDC, the first publicly listed BDC focused primarily on cannabis lending, has long pitched itself as a differentiated player in a crowded field. Its latest quarter confirms that pitch. Net investment income hit a record $10.0M ($0.44/share), the portfolio grew to its largest level in company history, and the company turned in what management called "record results this quarter that demonstrate the benefits of our differentiated strategy."
In an environment where other BDCs are struggling against credit performance, dividend coverage concerns and interest rate uncertainty, Chicago Atlantic BDC has continued to strengthen its position.
The numbers back the boast. The company's weighted average yield on debt investments is 15.8% versus 10.8% for the average public BDC, 100% of the debt portfolio is senior secured, and only 2.6% of the portfolio (at fair value) sits in software — a sector that has dragged down other BDCs. Under leverage is 0.18x debt-to-equity versus a 1.3x industry average, and there are no nonaccruals.
Net income has now risen for four consecutive quarters, from $8M in 2025Q2 to $9M in 2026Q1.
What changed this quarter? The most significant development wasn't in the financials — it was a policy shift. In April, the Department of Justice announced that state-licensed medical cannabis products will be moved from Schedule I to Schedule III. “The Department of Justice took a significant step announcing that state licensed medical cannabis products will be moved from Schedule I to Schedule III.” — Peter Sack, Chief Executive Officer · 2026-05-14 The rescheduling eliminates the onerous 280E tax code, and while the company said it would not underwrite based on "potential future regulatory reform," the long-term credit quality of its borrowers could improve materially.
A second hearing on recreational rescheduling is scheduled for June 29, with a ruling expected by July 15. Management sees that as potentially "tremendous impact on the economics of the broader cannabis industry," including a pickup in capital markets and M&A activity.
Record Deployment, Bigger Ambitions
Beyond the policy tailwind, the company executed aggressively. It funded $93.9M across seven portfolio companies, including three new borrowers, and net investment activity was $32M. “The first quarter of 2026 was our most active origination period to date from both a gross and net deployment perspective.” — Bernardino Colonna, President · 2026-05-14 The pipeline across the Chicago Atlantic platform stands at about $810M, split between ~$482M in cannabis and ~$328M in non-cannabis opportunities.
That non-cannabis book is a deliberate part of the strategy. Dino Colonna explained that these are "much smaller positions" and the target is for non-cannabis to be 20–30% of the portfolio. This diversification gives the BDC another growth engine and reduces single-sector concentration. Notably, the company filed a $500M shelf registration to eventually tap the unsecured debt market, giving it "additional financial flexibility" beyond its $100M credit facility.
The shelf is significant because it addresses a key constraint. The company's 0.18x leverage is far below the BDC average, and management has consistently said it will stay "well below" industry leverage. But the shelf opens the door to more efficient funding. As Tom Geoffroy put it, they could “opportunistically use additional leverage deployed into high-quality, high-yielding assets” — Thomas Geoffroy, Interim Chief Financial Officer · 2026-05-14 to be "accretive to earnings."
The company also maintained its $0.34 dividend, the seventh consecutive quarter at that level. With record NII per share of $0.44, the dividend is comfortably covered.
A Different Lens on the Industry
The company's positioning reflects a long-held view that the U.S. cannabis market is not a monolith but "really a grouping of 40 individual states." In prior calls, management has stressed that they underwrite state-by-state and look for tailwinds like consolidation in Ohio, Missouri, and Maryland. The rescheduling news has only accelerated that activity. In the March call, Peter Sack noted that rescheduling “breathed a new, fresh air of optimism into the industry,” — Peter S. Sack, Chief Executive Officer · 2026-03-19 and we are now seeing the first tangible signs: more M&A, more operators seeking capital, and a larger pipeline.
The stock has responded. After a long decline (the full-history return is -28.5% from a 2022 peak), the last 90 days have been positive at +8.5%. The market appears to be starting to price in the improving fundamentals and the regulatory horizon.
Risks and Watch Items
The company remains highly concentrated — 76% of the portfolio is still in cannabis, and while that sector is improving, it is still federally illegal at the recreational level. The rescheduling hearings could disappoint, and the company itself says it underwrites based on "today's regulatory framework, not potential future regulatory reform." That discipline is a double-edged sword: it protects the book, but it also means the company might not fully participate in a rapid M&A ramp if valuations run ahead.
Another watch item is the free cash flow. The company's FCF (less SBC) has been persistently negative in recent quarters, reaching -$21M in 2026Q1, driven largely by loan origination outflows. That's normal for a lender scaling up, but it means the company is reliant on external funding — which is exactly why the shelf matters.
Liabilities-to-assets rose to 18.5% in the latest quarter, up from 11% the prior quarter, reflecting the credit facility drawdown. Still, that's a leverage ratio most BDCs would envy.
The Bottom Line
Chicago Atlantic BDC is a name in motion. The record deployment, the expanding non-cannabis non-cannabis book, and the $500M shelf all point to a company that is positioning for a new phase of growth. The Schedule III rescheduling of medical cannabis is a company-specific catalyst that could improve credit quality across its entire debt investment portfolio. If the June hearing goes the right way, the recreational market could open up even more. Management has been careful not to over-promise — they have a history of disappointment with federal reform — but the setup today is the most constructive it has been in years.
“We believe the opportunistic use of additional leverage deployed into high-quality, high-yielding assets and be accretive to earnings and supportive towards shareholder returns.” — Thomas Geoffroy, Interim Chief Financial Officer · 2026-05-14
That, in a nutshell, is the thesis: a disciplined lender, a tailwind from policy, and a growing toolkit to fund more loans. For a stock that has been beaten down for years, the recent 90-day up-move could be the start of a re-rating.